Back to search
Spinocerebellar Ataxia Type 3
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Spinocerebellar Ataxia Type 3 trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Spinocerebellar Ataxia Type 3 trials you may qualify forThe goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic di…
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, i…
Human fibroblasts and possibly other human somatic cells may be reprogrammed into induced pluripotent stem (iPS) cells by the forced expression of transcription…
The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar At…
The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebel…